Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Allbirds IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Inovio Pharmaceuticals Inc — how do they compare? Allbirds Inc trades at $2.57 (market cap $30.00M), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 2.6× Allbirds Inc's market cap. Which is the better fit depends on your goals.

BIRDINO
Market Cap
$30.00M$78.55M
Sector
Consumer CyclicalHealth
52-Week High
$16.99$2.87
52-Week Low
$2.21$0.66
Enterprise Value
$48.86M$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $2.56, down 0.78% on the day, as the company completes its pivot from footwear to AI infrastructure. Despite negative profitability metrics and declining revenue trends, the stock has shown volatility following recent strategic announcements including a name change and new CEO appointment. Technical indicators show mixed signals with a bullish overall rating but bearish moving averages, while fundamental challenges persist with negative net income margins and cash flow concerns.

The outlook remains speculative as BIRD transitions to AI infrastructure, creating both opportunity and significant risk. While analyst sentiment leans cautious with 79% hold ratings, recent leadership changes and strategic pivot could drive future growth if execution improves. Key risks include sustained cash burn, competitive AI market pressures, and the challenge of establishing credibility in a new industry segment.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO